Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 12/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5578558 | 0.91 | TACR1 (0.39) | TACR1HDAC1HDAC6HDAC8NPY5R | |
| SCHEMBL5578877 | 0.87 | MEN1 (0.36) | TACR1HDAC1HDAC6HDAC8NPY5R | |
| SCHEMBL5578725 | 0.84 | AVPR1A (0.46) | — | |
| SCHEMBL5578579 | 0.80 | HDAC8 (0.35) | TACR1HDAC8 | |
| SCHEMBL5578492 | 0.78 | HSD11B1 (0.39) | TACR1 | |
| SCHEMBL5578574 | 0.73 | HDAC1 (0.51) | TACR1HDAC1HDAC6HDAC8NPY5R | |
| SCHEMBL13209389 | 0.70 | HDAC1 (0.47) | TACR1HDAC1HDAC6HDAC8NPY5R | |
| SCHEMBL5578911 | 0.70 | HDAC1 (0.49) | TACR1HDAC1HDAC6HDAC8NPY5R | |
| SCHEMBL2853081 | 0.68 | CHRM1 (0.41) | — | |
| SCHEMBL2861866 | 0.68 | MEN1 (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005063745-A9 | NOVEL SPIROINDOLINE OR SPIROISOQUINOLINE COMPOUNDS, METHODS OF USE AND COMPOSITIONS THEREOF | ARENA PHARM INC (US) | 2007-02-01 | — | — | WO | claimed |
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | ARENA PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254903-A1 | Novel Spiroindoline or Spiroisoquinoline Compounds, Methods of Use and Compositions Thereof | REN, AVPR2, RECQL | TACR1 224/4885HDAC1 885/4885HDAC6 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.